Risk factors of ciprofloxacin resistance in urinary Escherichia coli isolates

Journal of Microbiology, Immunology and Infection

Volumn 41, Issue 4, 2008, Pages 325-331

  Lin, Chun Yu ^a   Huang, Shu Hua ^b   Chen, Tun Chieh ^a,c   Lu, Po Liang ^a,c,d   Lin, Wei Ru ^a   Chen, Yen Hsu ^a,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NONE   (Taiwan)

Author keywords

Ciprofloxacin; Drug resistance, bacterial; Escherichia coli; Risk factors; Urinary tract

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFMETAZOLE; CEFTIZOXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MINOCYCLINE; MONOBACTAM; NETILMICIN; QUINOLONE DERIVATIVE; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; ESCHERICHIA COLI; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RISK FACTOR; URINARY TRACT INFECTION; URINE CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUINOLONES; RISK FACTORS; TAIWAN; URINARY CATHETERIZATION; URINARY TRACT INFECTIONS;

EID: 57649123164     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Lau SM, Peng MY, Chang FY. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection. J Microbiol Immunol Infect. 2004;37:185-91.
2. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, et al; Israeli Urinary Tract Infection Group. Empiric use of trimethoprim- sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis. 2002;34:1165-9.
3. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. Clin Infect Dis. 2001;33:615-21.
4. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999;29:745-58.
5. Infectious Diseases Society of the Republic of China; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; Lee CY's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for antimicrobial therapy of urinary tract infections in Taiwan. J Microbiol Immunol Infect. 2000;33:271-2.
6. Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis. 2002;8:132-7.
7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 9th informational supplement. NCCLS document M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
8. Arslan H, Azap OK, Ergönül O, Timurkaynak F; Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005;56:914-8.
9. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117-20.
10. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. 2004;38:1148-52.
11. Peña C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995;39:520-4.
12. Richard P, Delangle MH, Raffi F, Espaze E, Richet H. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. Clin Infect Dis. 2001;32:162-6.
13. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006;50:2251-4.
14. Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis. 2005;40:e84-6.
15. Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control. 2004;32:177-83.
16. Trautner BW, Hull RA, Darouiche RO. Prevention of catheter-associated urinary tract infection. Curr Opin Infect Dis. 2005;18:37-41.
17. Kunin CM. Urinary-catheter-associated infections in the elderly. Int J Antimicrob Agents. 2006;28(Suppl 1):S78-81.
18. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-22.
19. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135-8.
20. Hsueh PR, Chen WH, Luh KT. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents. 2005;26:463-72.
21. Lepelletier D, Caroff N, Reynaud A, Richet H. Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis. 1999;29:548-52.
22. Kunin CM. Nosocomial urinary tract infections and the indwelling catheter: what is new and what is true? Chest. 2001;120:10-2.
23. McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother. 2001;45:3084-91.
24. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM; Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005;40:643-54.